Core Insights - Amgen Inc. is a global biotechnology company with a market cap of $206.4 billion, focusing on innovative human therapeutics for serious diseases [1] - The company is classified as a "mega-cap" stock, with a diverse portfolio that includes leading treatments for various health conditions [2] Financial Performance - Amgen's shares have seen a marginal decline from a 52-week high of $385.12, but have increased by 14.5% over the past three months, outperforming the Dow Jones Industrials Average's 5.9% rise [3] - Over the past 52 weeks, AMGN stock is up 23.6%, exceeding the Dow's 13.2% gain, and has risen nearly 17% year-to-date, compared to the Dow's 2.3% return [6] - Following Q4 2025 results, Amgen's shares jumped 8.2% after reporting $9.9 billion in revenue and adjusted EPS of $5.29, with strong forward guidance for 2026 [7] Market Position and Analyst Sentiment - Despite outperforming the Dow, Amgen's stock has underperformed compared to Gilead Sciences, which has seen a 20.3% YTD increase and a 33% rise over the past 52 weeks [8] - Analysts maintain a "Moderate Buy" consensus rating for AMGN stock, with the current trading price above the mean price target of $355.83 [8]

Core Viewpoint - Amgen is experiencing significant momentum, trading near 52-week highs with an 8% increase in the latest session, indicating strong institutional interest [1] Financial Performance - In Q4 2025, Amgen reported total revenues of approximately $9.9 billion, reflecting a 9% increase, while full-year revenues reached about $36.8 billion, up 10% [2] - Over the last three months, Amgen's stock has risen about 13.7%, and it is up roughly 11% year-to-date, showcasing steady accumulation in a $193 billion company [3] Stock Breakout Significance - The breakout to a 52-week high signals momentum capital attraction and a self-reinforcing setup, supported by a revenue growth rate of 10% for a mature biopharma franchise [4] - Amgen's valuation is reasonable, trading at a forward P/E of 15.6x, suggesting that the market is beginning to recognize the sturdiness of its forward earnings path [7] Product Portfolio and Pipeline - Amgen's strength lies in its diverse portfolio of therapies across various therapeutic areas, including inflammation, oncology, and rare diseases, with established products like Enbrel and newer assets contributing to growth [6] - The company is focused on expanding its growth engine beyond legacy products, with the pipeline providing optionality and commercial execution driving cash generation [12] Earnings and Valuation - Current-year EPS is approximately $22.33, with next-year EPS expected to be around $22.92, indicating consistent performance rather than hypergrowth [8] - The market is currently valuing Amgen at a mid-teens forward multiple despite delivering double-digit revenue growth, highlighting a potential mismatch that could lead to a breakout [9] Analyst Sentiment and Price Targets - Recent analyst upgrades reflect improving sentiment, with RBC raising its target to $360, Goldman Sachs to $415, and Cantor Fitzgerald to $350, indicating a consensus on Amgen's growth potential [10] Future Catalysts - Key catalysts include continued portfolio expansion and pipeline progress, which are essential for maintaining revenue growth and profitability [12] - The relative attractiveness of Amgen compared to mega-cap tech stocks, with a forward P/E of 15.6x, presents a favorable risk/reward profile [15] Conclusion - Amgen's stock hitting 52-week highs is a bullish indicator supported by strong fundamentals, reasonable valuation, and multiple growth catalysts, positioning it as a core large-cap healthcare winner [16][17]

Core Insights - Amgen reported revenue of $9.87 billion for the quarter ended December 2025, reflecting an 8.6% increase year-over-year and a surprise of +4.23% over the Zacks Consensus Estimate of $9.47 billion [1] - The earnings per share (EPS) was $5.29, slightly down from $5.31 in the same quarter last year, with an EPS surprise of +11.18% compared to the consensus estimate of $4.76 [1] Financial Performance Metrics - Amgen's stock has returned +7.5% over the past month, outperforming the Zacks S&P 500 composite's +1.8% change, and currently holds a Zacks Rank 3 (Hold) [3] - Product sales for BLINCYTO in the U.S. were $270 million, which is a +10.2% change year-over-year but below the estimated $283.5 million [4] - KYPROLIS sales in the ROW were $111 million, representing an -18.4% change year-over-year, also below the estimated $130.37 million [4] - Repatha sales in the U.S. reached $517 million, exceeding the estimate of $451.25 million, marking a +64.1% year-over-year increase [4] - Other revenues amounted to $499 million, surpassing the average estimate of $396.39 million, reflecting a +34.9% year-over-year change [4] - Total product sales were $9.37 billion, exceeding the average estimate of $9.09 billion, with a year-over-year change of +7.5% [4] - Otezla sales totaled $625 million, slightly above the estimate of $621.09 million, with a year-over-year change of +0.2% [4] - Total sales for KYPROLIS were $351 million, below the estimate of $362.31 million, representing a -5.7% year-over-year change [4] - Total sales for BLINCYTO were $413 million, below the estimate of $435.33 million, with an +8.4% year-over-year change [4] - Total sales for Repatha reached $870 million, exceeding the estimate of $811.51 million, marking a +43.6% year-over-year increase [4] - Total sales for XGEVA were $447 million, slightly below the estimate of $453.76 million, representing a -20.3% year-over-year change [4] - Total sales for Prolia were $1.05 billion, exceeding the estimate of $974.58 million, with a -9.5% year-over-year change [4]

Core Viewpoint - Amgen (AMGN) is expected to report quarterly earnings of $4.74 per share, a decline of 10.7% year-over-year, with revenues projected at $9.46 billion, reflecting a 4.2% increase compared to the previous year [1]. Earnings Estimates - The consensus EPS estimate has been revised upward by 0.1% over the past 30 days, indicating analysts have adjusted their projections positively [2]. - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between these revisions and short-term stock price performance [3]. Revenue and Product Sales Projections - Analysts predict 'Revenue- Other revenues' will reach $402.12 million, an increase of 8.7% from the prior-year quarter [5]. - 'Revenue- Product sales' is expected to be $9.04 billion, reflecting a 3.7% increase year-over-year [5]. - 'Product Sales- Vectibix- Total' is projected at $279.69 million, indicating a 13.7% increase from the previous year [5]. Specific Product Sales Estimates - 'Product Sales- Enbrel- Total' is estimated at $649.46 million, showing a significant decline of 36% year-over-year [6]. - 'Product Sales- Neulasta- U.S.' is projected at $56.02 million, down 22.2% from the year-ago quarter [6]. - 'Product Sales- Neulasta- ROW' is expected to reach $19.40 million, reflecting a 25.4% decline [6]. - 'Product Sales- BLINCYTO- ROW' is estimated at $152.62 million, an increase of 12.2% year-over-year [7]. - 'Product Sales- Repatha- U.S.' is projected at $442.32 million, indicating a substantial increase of 40.4% from the previous year [7]. - 'Product Sales- Repatha- ROW' is expected to be $360.19 million, reflecting a 23.8% increase [8]. - 'Product Sales- BLINCYTO- U.S.' is projected at $287.58 million, indicating a 17.4% increase [8]. - 'Product Sales- KYPROLIS- U.S.' is expected to reach $228.82 million, showing a slight decline of 3% year-over-year [8]. - 'Product Sales- KYPROLIS- ROW' is projected at $130.37 million, reflecting a 4.1% decline [9]. Stock Performance - Amgen shares have increased by 4.6% over the past month, outperforming the Zacks S&P 500 composite, which has risen by 0.8% [9].

Core Insights - BeOne Medicines Ltd. reported a revenue of $1.41 billion for the quarter ended September 2025, reflecting a 41% increase year-over-year and a surprise of +5.36% over the Zacks Consensus Estimate of $1.34 billion [1] - The company's EPS for the quarter was $1.09, a significant improvement from -$1.15 in the same quarter last year, resulting in an EPS surprise of +51.39% compared to the consensus estimate of $0.72 [1] Revenue Breakdown - Product Revenue from TEVIMBRA was $190.62 million, slightly below the average estimate of $198.95 million from three analysts [4] - Product Revenue from BRUKINSA (Zanubrutinib) reached $1.04 billion, exceeding the three-analyst average estimate of $1.01 billion [4] - Net product revenues totaled $1.4 billion, surpassing the average estimate of $1.35 billion and representing a +40.4% change compared to the year-ago quarter [4] - Product Revenue from KYPROLIS was $18.37 million, below the average estimate of $20.11 million based on two analysts [4] - Product Revenue from BLINCYTO was $30.48 million, exceeding the two-analyst average estimate of $25.67 million [4] - Product Revenue from POBEVCY was $10.5 million, below the two-analyst average estimate of $12.33 million [4] - Product Revenue from Other sources was $20.11 million, slightly above the average estimate of $17.76 million from two analysts [4] - Product Revenue from XGEVA was $84.24 million, significantly above the average estimate of $66.23 million based on two analysts [4] Stock Performance - Over the past month, shares of BeOne Medicines Ltd. have returned -8.5%, contrasting with the Zacks S&P 500 composite's +1.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - BeOne Medicines Ltd. reported a revenue of $1.41 billion for the quarter ended September 2025, marking a 41% increase year-over-year and exceeding the Zacks Consensus Estimate by 5.36% [1] - The company's EPS for the quarter was $1.09, a significant improvement from -$1.15 in the same quarter last year, resulting in an EPS surprise of 51.39% compared to the consensus estimate of $0.72 [1] Revenue Breakdown - Product Revenue from TEVIMBRA was $190.62 million, slightly below the estimated $198.95 million [4] - Product Revenue from BRUKINSA (Zanubrutinib) reached $1.04 billion, surpassing the average estimate of $1.01 billion [4] - Net product revenues totaled $1.4 billion, representing a 40.4% increase compared to the previous year and exceeding the estimated $1.35 billion [4] - Product Revenue from KYPROLIS was $18.37 million, below the average estimate of $20.11 million [4] - Product Revenue from BLINCYTO was $30.48 million, exceeding the average estimate of $25.67 million [4] - Product Revenue from POBEVCY was $10.5 million, below the average estimate of $12.33 million [4] - Product Revenue from Other sources was $20.11 million, slightly above the estimated $17.76 million [4] - Product Revenue from XGEVA was $84.24 million, significantly higher than the average estimate of $66.23 million [4] Stock Performance - Over the past month, BeOne Medicines Ltd. shares have returned -8.5%, contrasting with the Zacks S&P 500 composite's +1.3% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Core Insights - Analysts project Amgen (AMGN) will report quarterly earnings of $5.00 per share, reflecting a 10.4% decline year over year, with revenues expected to reach $8.94 billion, a 5.2% increase from the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been adjusted downward by 0.9% over the past 30 days, indicating a reassessment by covering analysts [1][2] - Revisions to earnings estimates are significant indicators for predicting investor actions regarding the stock [2] Revenue Projections - Analysts estimate 'Revenue- Other revenues' at $373.34 million, indicating a year-over-year change of +6.1% [4] - 'Revenue- Product sales' is projected to be $8.55 billion, reflecting a +4.8% change from the prior-year quarter [4] Product Sales Forecasts - 'Product Sales- BLINCYTO- Total' is expected to reach $412.70 million, showing a +26.2% change year over year [4] - 'Product Sales- Otezla- Total' is forecasted at $582.08 million, indicating a +3.2% change [5] - 'Product Sales- Neulasta- U.S.' is expected to be $60.90 million, reflecting a -27.5% change [5] - 'Product Sales- Repatha- U.S.' is projected at $367.86 million, indicating a +30.9% change [6] - 'Product Sales- BLINCYTO- U.S.' is expected to reach $298.45 million, reflecting a +25.9% change [7] Market Performance - Amgen shares have shown a return of -2.3% over the past month, compared to a +3.6% change in the Zacks S&P 500 composite [8]

Group 1 - BeOne Medicines Ltd. reported $1.32 billion in revenue for the quarter ended June 2025, a year-over-year increase of 41.6% [1] - The earnings per share (EPS) for the same period was $0.84, compared to -$1.15 a year ago, indicating a significant turnaround [1] - The reported revenue exceeded the Zacks Consensus Estimate of $1.24 billion by 6.17%, and the EPS surprise was 75% above the consensus estimate of $0.48 [1] Group 2 - Key product revenue included BRUKINSA at $949.84 million, TEVIMBRA at $193.52 million, and total product revenue net at $1.3 billion, all surpassing analyst estimates [4] - Collaboration revenue reached $13.22 million, a 64.9% increase compared to the year-ago quarter, exceeding the average estimate of $7.59 million [4] - Other notable product revenues included KYPROLIS at $19.42 million, BLINCYTO at $25.59 million, and XGEVA at $81.32 million, all of which met or exceeded analyst expectations [4] Group 3 - BeOne Medicines Ltd. shares have returned +25.7% over the past month, significantly outperforming the Zacks S&P 500 composite's +0.5% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Amgen reported a strong Q2 2025 with a 9% increase in GAAP revenue to $9.18 billion and a non-GAAP EPS of $6.02, exceeding analyst expectations [1][2][5] - The company emphasized pipeline advancements and product launches as key drivers of growth, despite a decline in free cash flow [1][4][5] Financial Performance - Non-GAAP EPS reached $6.02, a 21% increase from $4.97 in Q2 2024, surpassing the consensus estimate of $5.28 [2][5] - GAAP revenue was $9.18 billion, up 9% year-over-year, compared to $8.4 billion in Q2 2024 [2][5] - Non-GAAP operating margin improved to 48.9%, a 0.7 percentage point increase from the previous year [2][6] - Free cash flow decreased to $1.9 billion from $2.2 billion in Q2 2024, attributed to higher capital spending and tax payment timing [2][5][15] Product Performance - Sales growth varied across product lines, with Repatha and EVENITY increasing over 30%, while Prolia saw a 4% decline [7][8] - Rare disease products UPLIZNA and TAVNEOS experienced significant revenue increases of 91% and 55%, respectively [7][11] - Inflammation products showed mixed results, with TEZSPIRE growing 46% and Enbrel declining 34% [8] - Oncology products like IMDELLTRA reported strong growth, while older drugs faced competitive pressures [12][13] Pipeline and Innovation - Amgen's pipeline includes promising candidates like MariTide for obesity, which showed strong phase 2 data [10][12] - UPLIZNA is under FDA review for generalized myasthenia gravis, with a decision expected by December 14, 2025 [11] - The company is focusing on expanding its biosimilars portfolio, although pricing pressures are increasing [13][16] Strategic Focus - Amgen is committed to expanding its product pipeline and international market presence while investing in advanced manufacturing [4][16] - The company plans to maintain a capital spending target of $2.3 billion and has set a revenue target of $35.0–$36.0 billion for FY2025 [17][18] - Management highlighted the importance of new drug approvals and the impact of biosimilar competition on established products as key areas to monitor [19]

Core Insights - Amgen reported $9.18 billion in revenue for the quarter ended June 2025, a year-over-year increase of 9.4%, with an EPS of $6.02 compared to $4.97 a year ago, exceeding both revenue and EPS consensus estimates [1] Financial Performance - Revenue from product sales reached $8.77 billion, surpassing the average estimate of $8.5 billion, reflecting a 9.1% increase year-over-year [4] - Other revenues amounted to $408 million, exceeding the average estimate of $345.97 million, representing a year-over-year increase of 17.6% [4] - The EPS surprise was +14.45% compared to the consensus estimate of $5.26 [1] Product Sales Breakdown - Neulasta (ROW) sales were $19 million, below the estimate of $23.31 million, showing a year-over-year decline of 36.7% [4] - Neulasta (U.S.) sales were $63 million, compared to the estimate of $70.64 million, reflecting a 16% year-over-year decrease [4] - Otezla (ROW) sales were $106 million, slightly below the estimate of $112.78 million, with a year-over-year decline of 5.4% [4] - Nplate (U.S.) sales were $228 million, slightly above the estimate of $227.77 million, showing a year-over-year increase of 6.5% [4] - Vectibix sales totaled $305 million, exceeding the estimate of $277.53 million, with a year-over-year increase of 13% [4] - BLINCYTO sales were $384 million, slightly below the estimate of $385.77 million, but represented a significant year-over-year increase of 45.5% [4] - Enbrel sales were $604 million, significantly below the estimate of $804.22 million, reflecting a year-over-year decline of 33.6% [4] - LUMAKRAS/LUMYKRAS sales were $90 million, in line with the estimate of $90.65 million, showing a year-over-year increase of 5.9% [4] Stock Performance - Amgen's shares returned +3.1% over the past month, outperforming the Zacks S&P 500 composite's +1% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]